VALENCIA, SPAIN--(NewMediaWire - Jan 23, 2017)
- Zenosense, Inc. (OTCQB: ZENO)
("Zenosense", the "Company"), a healthcare technology company
primarily focused on the development and commercialization of MIDS
Cardiac™, a Point of Care ("POC") handheld device for the early
detection of certain cardiac event biomarkers to significantly
accelerate the triage, diagnosis, treatment and disposition of
patients reporting chest pain and with suspected acute myocardial
infarction (heart attack), is pleased to announce that MIDS Medical
Limited ("MML"), our 40% owned joint venture based at Sci-Tech,
Daresbury, UK has submitted a UK Intellectual Property Office
patent application for an additional MIDS detection method.
MML is focussed on applying its MIDS technology into a
rapid-test, cardiac event detection device, MIDS Cardiac™. The
first phase is intended to prove the MIDS technology platform as
highly sensitive for the detection and quantitation of magnetic
nanoparticles, the fundamental detection principle having been
previously proved by the MML Scientists.
MML is in the process of proving detection in two purpose built
bench rigs, the mechanical and electronic parts of which have been
largely manufactured and in assembly. The rigs are designed to test
two methods of nano-magnetic detection using a "Test Slide" design
common to both. The Test Slides are designed to be dosed with
highly accurate, very small quantities of nanoparticles and to
position that dose within the respective rigs for magnetic
detection and quantitation.
The first rig is a subsequent iteration of a design to prove a
patented technology exclusive to MML. Very small quantities of sub
100 nanometre nanoparticles were detected magnetically during
testing of the original iteration of this rig in late 2016,
delivering results directly in line with the development program
expectations. The subsequent iteration rig in assembly is designed
to gather definitive quantitative data under highly controlled
conditions (several rig iterations were anticipated within the
development program).
The second rig is designed to explore the viability of a
variation of the magnetic detection method whereby the magnetic
detection is carried out by a Hall Sensor in a "Magnetic Bridge"
structure. If it can be proven to operate to an adequate
sensitivity suitable for a POC device, the new Magnetic Bridge
method may offer substantial production advantages over the first
method. These potential advantages include the considerable
simplification of a microfluidic test strip design and a reduction
in the Hall sensor requirement.
On January 19, 2017 MML submitted a patent application for this
new detection method: "Device and method for accurate
measurement of magnetic particles in assay apparatus". MML
believes that both detection methods are equally ground breaking
and commercially viable, should either be proven as feasible to
embody in a POC device.
We believe that, in addition to cardiac markers, the MIDS
technology can be applied across a very wide spectrum of medical
tests. Proof of detection is the first step in applying the MIDS
technology to cardiac markers, and other immunoassay tests. The
Company believes there is an enormous potential market for highly
accurate cardiac marker assays conducted by a hand held device at
the POC. The Company's target is to develop a hand-held device
which can achieve Gold Standard laboratory accuracy or better, with
results delivered at the POC within minutes.
About Zenosense, Inc.
Zenosense Inc.'s primary focus, through our joint venture
ownership in MIDS Medical Ltd., is the development of a
cost-effective, hand-held Point of Care rapid cardiac diagnostic
device, MIDS Cardiac™, and is also the holder of an exclusive
global license agreement to develop and market effective medical
devices for use in hospitals and primary healthcare settings
targeting the early detection of both deadly bacteria and certain
cancers in the exhaled breath of patients.
To find out more about Zenosense (OTCQB: ZENO),
visit our website at www.zenosense.com.
Forward-Looking Statements
Statements in this news release that are not statements of
historical fact are forward-looking statements, which are subject
to certain risks and uncertainties. Forward-looking statements
can often be identified by words such as "expects," "intends,"
"plans," "may," "could," "should," "anticipates," "likely,"
"believes" and words of similar import. Forward-looking
statements are based on current facts and analyses and other
information that are based on forecasts of future results,
estimates of amounts not yet determined and assumptions of
management. Actual results may differ materially from those
expressed or implied by forward-looking statements due to a variety
of factors that may or may not be foreseeable or within the
reasonable control of the Company. Readers are cautioned not
to place undue reliance on such forward-looking
statements. Additional information on risks and other factors
that may affect the business and financial results of the Company
can be found in filings of the Company with the U.S. Securities and
Exchange Commission, including without limitation the section
entitled "Risk Factors" in the Company's Annual Report on Form 10-K
for the year ended December 31, 2015 filed on filed on May 23,
2016, and in Company reports filed subsequently
thereto. Except as otherwise required by law, the Company
disclaims any obligations or undertaking to publicly release any
updates or revisions to any forward-looking statement contained in
this news release to reflect any change in the Company's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based.
Respective statements concerning the development of both MIDS
Cardiac™ and other devices under development have been made based
on information obtained from MIDS Medical Ltd. and Zenon Biosystem,
which the Company believes to be accurate, but have not been
independently verified.